The newly approved test, developed by Fujirebio Diagnostics, Inc., is designed for patients aged 55 and older who are ...

The test can aid doctors in determining whether a patient’s memory problems are due to Alzheimer’s or a number of other ...

The Food and Drug Administration has cleared Fujirebio Diagnostics’ blood test to diagnose Alzheimer’s disease, the regulator ...

The Lumipulse Alzheimer's blood test is the first of a new generation of tests that may replace brain scans and spinal taps to detect the disease.

The FDA has approved the first blood test for diagnosing Alzheimer’s disease, which could speed the path to treatment for ...

U.S. health officials have endorsed the first blood test that can help diagnose Alzheimer’s. The test would help identify ...

Lecanemab binds with high affinity to soluble amyloid-beta protofibrils. It won full FDA approval in July 2023 based on trial ...

The findings show that memory clinics can have “the infrastructure and expertise to safely administer and care for patients ...

While similar to lecanemab (Leqembi), an earlier FDA-approved infusion, donanemab introduces new possibilities in how Alzheimer’s can be managed—and potentially paused. Donanemab is a ...

Analyst concerns centered on execution risks for LEQEMBI’s rollout and competitive dynamics in the Alzheimer’s market. Biogen’s Q1 2025 earnings call underscored its transition toward a ...

Eisai Europe and Biogen Idec have announced the validation of a Marketing Authorisation Variation by the Medicines and Healthcare products Regulatory Agency (MHRA) for lecanemab – marketed as Leqembi ...